ITOS Key Statistics, Chart & Performance
The current stock price of ITOS is 10.15 USD. In the past month the price increased by 0.1%. In the past year, price decreased by -39.76%.
ITOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About ITOS
Company Profile
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The company is headquartered in Watertown, Massachusetts and currently employs 173 full-time employees. The company went IPO on 2020-07-24. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. The company is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Company Info
ITEOS THERAPEUTICS INC
321 Arsenal Street, Bldg 312, Floor 3, Suite 301
Watertown MASSACHUSETTS 02142 US
CEO: Michel Detheux
Employees: 173
Phone: 18572044583
ITEOS THERAPEUTICS INC / ITOS FAQ
What does ITOS do?
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The company is headquartered in Watertown, Massachusetts and currently employs 173 full-time employees. The company went IPO on 2020-07-24. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. The company is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
What is the current price of ITOS stock?
The current stock price of ITOS is 10.15 USD. The price increased by 0.2% in the last trading session.
What is the dividend status of ITEOS THERAPEUTICS INC?
ITOS does not pay a dividend.
How is the ChartMill rating for ITEOS THERAPEUTICS INC?
ITOS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for ITOS stock?
The Revenue of ITEOS THERAPEUTICS INC (ITOS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of ITOS stock?
ITEOS THERAPEUTICS INC (ITOS) has a market capitalization of 448.73M USD. This makes ITOS a Small Cap stock.
Who owns ITEOS THERAPEUTICS INC?
You can find the ownership structure of ITEOS THERAPEUTICS INC (ITOS) on the Ownership tab.
ITOS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ITOS. When comparing the yearly performance of all stocks, ITOS is a bad performer in the overall market: 89.45% of all stocks are doing better.
ITOS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ITOS. No worries on liquidiy or solvency for ITOS as it has an excellent financial health rating, but there are worries on the profitability.
ITOS Financial Highlights
Over the last trailing twelve months ITOS reported a non-GAAP Earnings per Share(EPS) of -4.31. The EPS decreased by -43.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.57% | ||
| ROE | -27.22% | ||
| Debt/Equity | 0 |
ITOS Forecast & Estimates
10 analysts have analysed ITOS and the average price target is 10.56 USD. This implies a price increase of 4% is expected in the next year compared to the current price of 10.15.
For the next year, analysts expect an EPS growth of -7.51% and a revenue growth -100% for ITOS